Schistosomiasis cirrhosis (SAC), as the core pathological outcome of late-stage schistosomiasis, is an important challenge to global public health. Notably, there is still a significant disease burden, especially in the traditional endemic areas, such as the Yangtze River Basin in China. SAC has unique pathogenic characteristics, including insect-derived molecular-driven disease, chronic inflammation dominated by Th2 immunity, delayed pathogenicity, noticeable symptoms of portal hypertension, and an absence of significant correlation with liver cancer. Therefore, future research should focus on the determinants of individual susceptibility to SAC onset, the core mechanism of liver lesion progression post-pathogen clearance, time nodes, and intervention methods. Additionally, finding the high-risk individuals, analyzing of pathological mechanisms, and optimizing intervention strategies will help in promoting the development of clinical prevention and control and translational research.
血吸虫病肝硬化(SAC)作为晚期血吸虫病的核心病理结局,是全球公共卫生的重要挑战,尤其在我国长江流域等传统流行区仍存在显著疾病负担。SAC致病特点独特,包括虫源分子驱动疾病、以Th2免疫为主的慢性炎症、迟发致病、门静脉高压症状突出、与肝癌关系不显著等。未来研究应聚焦SAC发病个体易感性的决定因素、清除病原体后肝脏病变进展的核心机制,以及对SAC的干预时间节点与手段,这有助于识别高危个体、解析病理机制并优化干预策略,从而推动临床防控和转化研究发展。.